Therefore, leveraging CD74 as a therapeutic target to deliver potent GC drugs to simultaneously suppress these key pathogenic immune cell types in SLE, compared to single-pathway modulation, theoretically could exert broader therapeutic effects, and may avoid the side effects of traditional GC drugs as well. Here, CD74 is linked to systemic lupus erythematosus.